These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 23302469)

  • 1. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.
    Qiu S; Lin S; Hu D; Feng Y; Tan Y; Peng Y
    J Transl Med; 2013 Jan; 11():10. PubMed ID: 23302469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
    Chen H; Li X; Li W; Zheng H
    J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microrna-1224-5p Is a Potential Prognostic and Therapeutic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Analyses.
    Wei X; Zhang QM; Liu C; Wu S; Nong WX; Ge YY; Lin LN; Li F; Xie XX; Luo B
    Curr Med Sci; 2022 Jun; 42(3):584-596. PubMed ID: 35678909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS.
    Takkar S; Sharma V; Ghosh S; Suri A; Sarkar C; Kulshreshtha R
    Cell Oncol (Dordr); 2021 Apr; 44(2):433-451. PubMed ID: 33469841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
    Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
    Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
    Yerukala Sathipati S; Huang HL; Ho SY
    BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin.
    Herman A; Gruden K; Blejec A; Podpečan V; Motaln H; Rožman P; Hren M; Zupančič K; Veber M; Verbovšek U; Lah Turnšek T; Porčnik A; Koršič M; Knežević M; Jeras M
    PLoS One; 2015; 10(5):e0125791. PubMed ID: 25950799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics analysis of miRNA expression profile between primary and recurrent glioblastoma.
    Bo LJ; Wei B; Li ZH; Wang ZF; Gao Z; Miao Z
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3579-86. PubMed ID: 26502847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
    Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
    Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-330-3p and miR-485-5p as biomarkers for glioblastoma: An integrated bioinformatics and experimental study.
    Rahmati Y; Alivand M; Mollanoori H
    Comput Biol Chem; 2021 Jun; 92():107458. PubMed ID: 33761401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells.
    C Yilmaz U; Bagca BG; Karaca E; Durmaz A; Durmaz B; Aykut A; Kayalar H; Avci CB; Susluer SY; Pariltay E; Gunduz C; Cogulu O
    Anticancer Agents Med Chem; 2022; 22(2):378-389. PubMed ID: 33949939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
    Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
    Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 4-miRNA signature to predict survival in glioblastomas.
    Hermansen SK; Sørensen MD; Hansen A; Knudsen S; Alvarado AG; Lathia JD; Kristensen BW
    PLoS One; 2017; 12(11):e0188090. PubMed ID: 29136645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
    Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
    J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
    Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
    Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression.
    Wu W; Yu T; Wu Y; Tian W; Zhang J; Wang Y
    J Exp Clin Cancer Res; 2019 Mar; 38(1):133. PubMed ID: 30898167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
    Chen J; Yang L; Wang X
    Cancer Biomark; 2017 Dec; 20(4):521-526. PubMed ID: 28946553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
    Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
    Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.